Celcuity (CELC) Long-Term Investments (2017 - 2018)

Celcuity's (CELC) quarterly Long-Term Investments came in at $3.9 million in Q3 2018, down 43.59% on a QoQ basis from $6.9 million in Q2 2018.

Celcuity (CELC) Long-Term Investments (2017 - 2018) Analysis & Trends

Celcuity (CELC) has 2 years of Long-Term Investments data on file, last reported at $3.9 million in Q3 2018.

Quarterly Long-Term Investments changed N/A year-over-year to $3.9 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $3.9 million (changed N/A YoY) and the FY2017 annual result came in at $7.2 million, changed N/A from the prior year.
Long-Term Investments eased to $3.9 million in Q3 2018, from $6.9 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $7.2 million in Q4 2017 to a low of $3.9 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	372.10 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.17 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Celcuity	4.50 Bn	4.50 Bn	-	-

Download Data